Last $22.43 USD
Change Today 0.00 / 0.00%
Volume 0.0
HLUKF On Other Exchanges
As of 8:10 PM 09/29/14 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (HLUKF) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/14 - $31.33
52 Week Low
10/11/13 - $20.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S (HLUKF)

Related News

No related news articles were found.

h lundbeck a/s (HLUKF) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

5,703 Employees
Last Reported Date: 08/7/14
Founded in 1915

h lundbeck a/s (HLUKF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (HLUKF) Key Developments

U.S. FDA Accepts Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S's Filing for Review of Brexpiprazole

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration has determined that the New Drug Application (NDA) for brexpiprazole for monotherapy in adult patients with schizophrenia and for adjunctive treatment of major depressive disorder (MDD) in adult patients is sufficiently complete to allow for a substantive review, and the NDA is considered filed as of September 9, 2014 (60 days after submission). The PDUFA date is July 11, 2015.

H. Lundbeck A/S Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 08:20 AM

H. Lundbeck A/S Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 08:20 AM. Venue: Medicon Village, Hörsalen, Scheelevägen 2, 223 63 Lund, Sweden. Speakers: Ulf Arne Wiinberg, Chief Executive Officer, President and Member of Executive Management.

H. Lundbeck A/S Initiates Launch of Antidepressant Brintellix in Denmark

H. Lundbeck A/S has initiated the launch of its antidepressant Brintellix in Denmark. This marks the first European launch and thereby the next step in the global introduction of Brintellix, which was commercially launched in the US in January 2014. Following the Danish launch, Brintellix, which is approved for treatment of major depressive episodes (MDE, hereafter referred to as "depression") in adults, will be introduced in several other European and International Markets during 2014 and 2015. Brintellix will be available and reimbursed in Denmark as second line treatment for depression, in line with the reimbursement dossier submitted and approved by Danish health authorities. Brintellix is a novel multimodal antidepressant, which has demonstrated significant efficacy in adult patients with depression as measured by traditional scales like MADRS or HAMD. It has also demonstrated improvement of cognitive performance in adult patients with depression, as measured with neuropsychological tests, as e.g. DSST or RAVLT.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HLUKF:US $22.43 USD 0.00

HLUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $43.04 USD -0.71
Emergent Biosolutions Inc $21.51 USD -0.18
Impax Laboratories Inc $24.17 USD -0.17
Lupin Ltd 1,396 INR -0.2999
Salix Pharmaceuticals Ltd $157.77 USD +1.99
View Industry Companies

Industry Analysis


Industry Average

Valuation HLUKF Industry Range
Price/Earnings 31.3x
Price/Sales 1.7x
Price/Book 1.8x
Price/Cash Flow 31.3x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at